Hypoxia imaging in gliomas with 18F-fluoromisonidazole PET: Toward clinical translation

Seminars in Nuclear Medicine

Volumn 45, Issue 2, 2015, Pages 136-150

  Bell, Christopher ^a,b   Dowson, Nicholas ^a   Fay, Mike ^c   Thomas, Paul ^c   Puttick, Simon ^b   Gal, Yaniv ^b   Rose, Stephen ^a,b  

^a CSIRO   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; FLUORODEOXYGLUCOSE F 18; RUBIDIUM 82; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; MISONIDAZOLE;

ANGIOGENESIS; ARTICLE; BOLD SIGNAL; CANCER GRADING; CANCER PROGNOSIS; CANCER STEM CELL; GLIOBLASTOMA; GLIOMA; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; TOMOTHERAPY; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANIMAL; CELL HYPOXIA; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; SCINTISCANNING; TRANSLATIONAL RESEARCH;

ANIMALS; CELL HYPOXIA; GLIOMA; HUMANS; MISONIDAZOLE; POSITRON-EMISSION TOMOGRAPHY; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT FAILURE;

EID: 84924066361     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2014.10.001     Document Type: Review

References (186)

1. K.R. Swanson, E.C. Alvord Jr, and J.D. Murray Virtual brain tumours (gliomas) enhance the reality of medical imaging and highlight inadequacies of current therapy Br J Cancer 86 2002 14 18
2. J.C. Buckner Factors influencing survival in high-grade gliomas Semin Oncol 30 2003 10 14
3. W.J. Curran Jr, C.B. Scott, and J. Horton Recursive partitioning analysis of prognostic factors in Three Radiation Therapy Oncology Group malignant glioma trials J Natl Cancer Inst 85 1993 704 710
4. L.M. DeAngelis Brain tumors N Engl J Med 344 2001 114 123
5. A. Behin, K. Hoang-Xuan, and A.F. Carpentier Primary brain tumours in adults Lancet 361 2003 323 331
6. T. Gorlia, M.J. van den Bent, and M.E. Hegi Nomograms for predicting survival of patients with newly diagnosed glioblastoma: Prognostic factor analysis of EORTC and NCIC trial 26981-22981/Ce.3 Lancet Oncol 9 2008 29 38
7. E.R. Laws, I.F. Parney, and W. Huang Survival following surgery and prognostic factors for recently diagnosed malignant glioma: Data from the Glioma Outcomes Project J Neurosurg 99 2003 467 473
8. D.N. Louis, H. Ohgaki, and O.D. Wiestler The 2007 WHO classification of tumours of the central nervous system Acta Neuropathol 114 2007 97 109
9. R. Stupp, W.P. Mason, and M.J. van den Bent Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996
10. M.D. Walker, S.B. Green, and D.P. Byar Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery N Engl J Med 303 1980 1323 1329
11. B. Kim, E. Soisson, and C. Duma Treatment of recurrent high grade gliomas with hypofractionated stereotactic image-guided helical tomotherapy Clin Neurol Neurosurg 113 2011 509 512
12. J.L. Chan, S.W. Lee, and B.A. Fraass Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy J Clin Oncol 20 2002 1635 1642
13. B. Gulyas, and C. Halldin New PET radiopharmaceuticals beyond FDG for brain tumor imaging Q J Nucl Med Mol Imaging 56 2012 173 190
14. D.M. Brizel, G.S. Sibley, and L.R. Prosnitz Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck Int J Radiat Oncol Biol Phys 38 1997 285 289
15. R.A. Gatenby, H.B. Kessler, and J.S. Rosenblum Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy Int J Radiat Oncol Biol Phys 14 1988 831 838
16. P. Kolstad Intercapillary distance, oxygen tension and local recurrence in cervix cancer Scand J Clin Lab Invest Suppl 106 1968 145 157
17. S. Rafii, D. Lyden, and R. Benezra Vascular and haematopoietic stem cells: Novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2 2002 826 835
18. A.C. Begg, F.A. Stewart, and C. Vens Strategies to improve radiotherapy with targeted drugs Nat Rev Cancer 11 2011 239 253
19. M. Kioi, H. Vogel, and G. Schultz Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice J Clin Invest 120 2010 694 705
20. D. Lyden, K. Hattori, and S. Dias Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth Nat Med 7 2001 1194 1201
21. J.P. Greenfield, W.S. Cobb, and D. Lyden Resisting arrest: A switch from angiogenesis to vasculogenesis in recurrent malignant gliomas J Clin Invest 120 2010 663 667
22. F. Pajonk, E. Vlashi, and W.H. McBride Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited Stem Cells 28 2010 639 648
23. U. Bagci, G. Kramer-Marek, and D.J. Mollura Automated computer quantification of breast cancer in small-animal models using PET-guided MR Image co-segmentation EJNMMI Res 3 2013 49
24. P.E. Ricci, J.P. Karis, and J.E. Heiserman Differentiating recurrent tumor from radiation necrosis: Time for re-evaluation of positron emission tomography? Am J Neuroradiol 19 1998 407 413
25. S.K. Singh, C. Hawkins, and I.D. Clarke Identification of human brain tumour initiating cells Nature 432 2004 396 401
26. M. Al-Hajj, M.S. Wicha, and A. Benito-Hernandez Prospective identification of tumorigenic breast cancer cells Proc Natl Acad Sci U S A 100 2003 3983 3988
27. D. Bonnet, and J.E. Dick Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell Nat Med 3 1997 730 737
28. T. Lapidot, C. Sirard, and J. Vormoor A cell initiating human acute myeloid leukaemia after transplantation into SCID mice Nature 367 1994 645 648
29. T. Schatton, G.F. Murphy, and N.Y. Frank Identification of cells initiating human melanomas Nature 451 2008 345 349
30. C.M. Fillmore, and C. Kuperwasser Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy Breast Cancer Res 10 2008 R25-R25
31. + breast cancer-initiating cells to radiation J Natl Cancer Inst 98 2006 1777 1785
32. W.A. Woodward, M.S. Chen, and F. Behbod WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells Proc Natl Acad Sci U S A 104 2007 618 623
33. S. Bao, Q. Wu, and R.E. McLendon Glioma stem cells promote radioresistance by preferential activation of the DNA damage response Nature 444 2006 756 760
34. C.J. Chang, C.C. Hsu, and M.C. Yung Enhanced radiosensitivity and radiation-induced apoptosis in glioma CD133-positive cells by knockdown of SIRT1 expression Biochem Biophys Res Commun 380 2009 236 242
35. A. Eramo, L. Ricci-Vitiani, and A. Zeuner Chemotherapy resistance of glioblastoma stem cells Cell Death Differ 13 2006 1238 1241
36. S.L. Lomonaco, S. Finniss, and C. Xiang The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells Int J Cancer 125 2009 717 722
37. S.H. Chiou, C.L. Kao, and Y.W. Chen Identification of CD133-positive radioresistant cells in atypical teratoid/rhabdoid tumor PLoS One 3 2008 e2090-e2090
38. M.P. Mongiardi Angiogenesis and hypoxia in glioblastoma: A focus on cancer stem cells CNS Neurol Disord Drug Targets 11 2012 878 883
39. D.M. Brizel, R.K. Dodge, and R.W. Clough Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome Radiother Oncol 53 1999 113 117
40. J. Folkman What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82 1990 4 6
41. J.M. Brown, and W.R. Wilson Exploiting tumour hypoxia in cancer treatment Nat Rev Cancer 4 2004 437 447
42. M. Hockel, B. Vorndran, and K. Schlenger Tumor oxygenation: A new predictive parameter in locally advanced cancer of the uterine cervix Gynecol Oncol 51 1993 141 149
43. R.H. Thomlinson, and L.H. Gray The histological structure of some human lung cancers and the possible implications for radiotherapy Br J Cancer 9 1955 539 549
44. 2 distribution and bioreductive enzymes in human malignant brain tumors Int J Radiat Oncol Biol Phys 29 1994 427 431
45. E.J. Hall Radiobiology for the Radiologist (ed 4) 1994 JB Lippincott Company Philadelphia, PA
46. T. Helleday, J. Lo, and D.C. van Gent DNA double-strand break repair: From mechanistic understanding to cancer treatment DNA Repair (Amst) 6 2007 923 935
47. A. Menegakis, W. Eicheler, and A. Yaromina Residual DNA double strand breaks in perfused but not in unperfused areas determine different radiosensitivity of tumours Radiother Oncol 100 2011 137 144
48. E.P. Rogakou, D.R. Pilch, and A.H. Orr DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139 J Biol Chem 273 1998 5858 5868
49. S. Davda, and T. Bezabeh Advances in methods for assessing tumor hypoxia in vivo: Implications for treatment planning Cancer Metastasis Rev 25 2006 469 480
50. S.M. Evans, K.D. Judy, and I. Dunphy Hypoxia is important in the biology and aggression of human glial brain tumors Clin Cancer Res 10 2004 8177 8184
51. S.M. Evans, K.D. Judy, and I. Dunphy Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding Cancer Res 64 2004 1886 1892
52. 2 predicts survival in advanced cancer of the uterine cervix Radiother Oncol 26 1993 45 50
53. M. Nordsmark, J. Loncaster, and S.C. Chou Invasive oxygen measurements and pimonidazole labeling in human cervix carcinoma Int J Radiat Oncol Biol Phys 49 2001 581 586
54. M. Nordsmark, and J. Overgaard A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy Radiother Oncol 57 2000 39 43
55. M.E. Powell, D.R. Collingridge, and M.I. Saunders Improvement in human tumour oxygenation with carbogen of varying carbon dioxide concentrations Radiother Oncol 50 1999 167 171
56. S. Ceyssens, K. Van Laere, and T. de Groot [11C]Methionine PET, histopathology, and survival in primary brain tumors and recurrence Am J Neuroradiol 27 2006 1432 1437
57. W.L. Rumsey, J.M. Vanderkooi, and D.F. Wilson Imaging of phosphorescence: A novel method for measuring oxygen distribution in perfused tissue Science 241 1988 1649 1651
58. S.A. Vinogradov, P. Grosul, and V. Rozhkov Oxygen distributions in tissue measured by phosphorescence quenching Adv Exp Med Biol 510 2003 181 185
59. S. Zhang, M. Hosaka, and T. Yoshihara Phosphorescent light-emitting iridium complexes serve as a hypoxia-sensing probe for tumor imaging in living animals Cancer Res 70 2010 4490 4498
60. S.S. Foo, D.F. Abbott, and N. Lawrentschuk Functional imaging of intratumoral hypoxia Mol Imaging Biol 6 2004 291 305
61. M. Srinivas, A. Heerschap, and E.T. Ahrens (19)F MRI for quantitative in vivo cell tracking Trends Biotechnol 28 2010 363 370
62. T. Kitai, A. Tanaka, and A. Tokuka Quantitative detection of hemoglobin saturation in the liver with near-infrared spectroscopy Hepatology 18 1993 926 936
63. E.L. Hull, D.L. Conover, and T.H. Foster Carbogen-induced changes in rat mammary tumour oxygenation reported by near infrared spectroscopy Br J Cancer 79 1999 1709 1716
64. 2-Hb shifts and bloodflow Acta Neurol Scand Suppl 64 1977 452 453
65. C.W. Pennekamp, M.L. Bots, and L.J. Kappelle The value of near-infrared spectroscopy measured cerebral oximetry during carotid endarterectomy in perioperative stroke prevention; A review Eur J Vasc Endovasc Surg 38 2009 539 545
66. J.D. Chapman Hypoxic sensitizers - Implications for radiation therapy N Engl J Med 301 1979 1429 1432
67. J.D. Chapman, P. Zanzonico, and C.C. Ling On measuring hypoxia in individual tumors with radiolabeled agents J Nucl Med 42 2001 1653 1655
68. J.S. Rasey, W.J. Koh, and M.L. Evans Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: A pretherapy study of 37 patients Int J Radiat Oncol Biol Phys 36 1996 417 428
69. W.J. Koh, J.S. Rasey, and M.L. Evans Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole Int J Radiat Oncol Biol Phys 22 1992 199 212
70. A.R. Padhani, K.A. Krohn, and J.S. Lewis Imaging oxygenation of human tumours Eur Radiol 17 2007 861 872
71. K.R. Swanson, G. Chakraborty, and C.H. Wang Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas J Nucl Med 50 2009 36 44
72. J.S. Rasey, N.J. Nelson, and L. Chin Characteristics of the binding of labeled fluoromisonidazole in cells in vitro Radiat Res 122 1990 301 308
73. L.M. Cher, C. Murone, and N. Lawrentschuk Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18f-FDG PET, and immunohistochemical studies J Nucl Med 47 2006 410 418
74. N. Kawai, Y. Maeda, and N. Kudomi Correlation of biological aggressiveness assessed by 11C-methionine PET and hypoxic burden assessed by 18F-fluoromisonidazole PET in newly diagnosed glioblastoma Eur J Nucl Med Mol Imaging 38 2011 441 450
75. P.E. Valk, C.A. Mathis, and M.D. Prados Hypoxia in human gliomas: Demonstration by PET with fluorine-18-fluoromisonidazole J Nucl Med 33 1992 2133 2137
76. Y. Yamamoto, Y. Maeda, and N. Kawai Hypoxia assessed by 18F-fluoromisonidazole positron emission tomography in newly diagnosed gliomas Nucl Med Commun 33 2012 621 625
77. S.T. Lee, and A.M. Scott Hypoxia positron emission tomography imaging with 18F-fluoromisonidazole Semin Nucl Med 37 2007 451 461
78. D.C. Jette, L.I. Wiebe, and R.J. Flanagan Iodoazomycin riboside (1-(5'-iodo-5'-deoxyribofuranosyl)-2-nitroimidazole), a hypoxic cell marker. I. synthesis and in vitro characterization Radiat Res 105 1986 169 179
79. R.H. Mannan, V.V. Somayaji, and J. Lee Radioiodinated 1-(5-Iodo-5-Deoxy-Beta-d-arabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside: IAZA): A novel marker of tissue hypoxia J Nucl Med 32 1991 1764 1770
80. R.H. Mannan, J.R. Mercer, and L.I. Wiebe Radioiodinated azomycin pyranoside (IAZP): A novel non-invasive marker for the assessment of tumor hypoxia J Nucl Biol Med 36 1992 60 67
81. R. Hustinx, S.L. Eck, and A. Alavi Potential applications of PET imaging in developing novel cancer therapies J Nucl Med 40 1999 995 1002
82. D. Sorger, M. Patt, and P. Kumar [18F]fluoroazomycinarabinofuranoside (18FAZA) and [18F]fluoromisonidazole (18FMISO): A comparative study of their selective uptake in hypoxic cells and pet imaging in experimental rat tumors Nucl Med Biol 30 2003 317 326
83. C.J. Koch, J.S. Scheuermann, and C. Divgi Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma Eur J Nucl Med Mol Imaging 37 2010 2048 2059
84. J.S. Rasey, P.D. Hofstrand, and L.K. Chin Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia J Nucl Med 40 1999 1072 1079
85. D.R. Hwang, C.S. Dence, and T.A. Bonasera No-carrier-added synthesis of 3-[18F]fluoro-1-(2-nitro-1-imidazolyl)-2-propanol. A potential PET agent for detecting hypoxic but viable tissues Int J Rad Appl Instrum A 40 1989 117 126
86. A.V. Kachur, W.R. Dolbier Jr, and S.M. Evans Synthesis of new hypoxia markers EF1 and [18F]-EF1 Appl Radiat Isot 51 1999 643 650
87. H. Wada, R. Iwata, and T. Ido Synthesis of 1-[2-[18F]fluoro-1-(hydroxymethyl)-ethoxy]methyl-2-nitroimidazole ([18F]FENI), a potential agent for imaging hypoxic tissues by PET J Labelled Compounds Radiopharm 43 2000 785 793
88. D.J. Yang, S. Wallace, and A. Cherif Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia Radiology 194 1995 795 800
89. K. Chia, I.N. Fleming, and P.J. Blower Hypoxia imaging with PET: Which tracers and why? Nucl Med Commun 33 2012 217 222
90. Rajendran JG, Krohn KA: Imaging Tumour Hypoxia, in (eds): (ed). London, Springer-Verlag, 2002
91. A.M. Spence, M. Muzi, and K.R. Swanson Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: Correlation with time to progression and survival Clin Cancer Res 14 2008 2623 2630
92. J.G. Rajendran, D.A. Mankoff, and F. O'Sullivan Hypoxia and glucose metabolism in malignant tumors: Evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging Clin Cancer Res 10 2004 2245 2252
93. M.D. Szeto, G. Chakraborty, and J. Hadley Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas Cancer Res 69 2009 4502 4509
94. S. Valable, E. Petit, and S. Roussel Complementary information from magnetic resonance imaging and (18)F-fluoromisonidazole positron emission tomography in the assessment of the response to an antiangiogenic treatment in a rat brain tumor model Nucl Med Biol 38 2011 781 793
95. J.S. Rasey, J.J. Casciari, and P.D. Hofstrand Determining hypoxic fraction in a rat glioma by uptake of radiolabeled fluoromisonidazole Radiat Res 153 2000 84 92
96. S. Doblas, T. He, and D. Saunders Glioma morphology and tumor-induced vascular alterations revealed in seven rodent glioma models by in vivo magnetic resonance imaging and angiography J Magn Reson Imaging 32 2010 267 275
97. S. Valable, B. Lemasson, and R. Farion Assessment of blood volume, vessel size, and the expression of angiogenic factors in two rat glioma models: A longitudinal in vivo and ex vivo study NMR Biomed 21 2008 1043 1056
98. R.F. Barth, and B. Kaur Rat brain tumor models in experimental neuro-oncology: The C6, 9l, T9, Rg2, F98, BT4c, RT-2 and CNS-1 gliomas J Neurooncol 94 2009 299 312
99. A. Corroyer-Dulmont, E.A. Peres, and E. Petit Noninvasive assessment of hypoxia with 3-[18F]-fluoro-1-(2-nitro-1-imidazolyl)-2-propanol ([18F]-FMISO): A PET study in two experimental models of human glioma Biol Chem 394 2013 529 539
100. M.M. Kleiter, D.E. Thrall, and D.E. Malarkey A comparison of oral and intravenous pimonidazole in canine tumors using intravenous CCI-103F as a control hypoxia marker Int J Radiat Oncol Biol Phys 64 2006 592 602
101. H.J. Tochon-Danguy, J.I. Sachinidis, and F. Chan Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high grade glioma using [18F]fluoromisonidazole (FMISO) Nucl Med Biol 29 2002 191 197
102. F.G. Dhermain, P. Hau, and H. Lanfermann Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas Lancet Neurol 9 2010 906 920
103. P.Y. Wen, D.R. Macdonald, and D.A. Reardon Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group J Clin Oncol 28 2010 1963 1972
104. N. Galldiks, R. Ullrich, and M. Schroeter Volumetry of [11C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme Eur J Nucl Med Mol Imaging 37 2010 84 92
105. I.F. Dunn, O. Heese, and P.M. Black Growth factors in glioma angiogenesis: Fgfs, PDGF, EGF, and TGFS J Neurooncol 50 2000 121 137
106. I. Fischer, J.P. Gagner, and M. Law Angiogenesis in gliomas: Biology and molecular pathophysiology Brain Pathol 15 2005 297 310
107. Swanson KR: Methematical Modeling of the Growth and Control of Tumours. 1999
108. K.R. Swanson, C. Bridge, and J.D. Murray Virtual and real brain tumors: Using mathematical modeling to quantify glioma growth and invasion J Neurol Sci 216 2003 1 10
109. K.R. Swanson, R.C. Rostomily, and E.C. Alvord Jr A mathematical modelling tool for predicting survival of individual patients following resection of glioblastoma: A proof of principle Br J Cancer 98 2008 113 119
110. R. Bos, J.J. van Der Hoeven, and E. van Der Wall Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography J Clin Oncol 20 2002 379 387
111. A.C. Clavo, and R.L. Wahl Effects of hypoxia on the uptake of tritiated thymidine, l-leucine, l-methionine and FDG in cultured cancer cells J Nucl Med 37 1996 502 506
112. S.M. Evans, S.M. Hahn, and D.P. Magarelli Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation Am J Clin Oncol 24 2001 467 472
113. A.M. Spence, M. Muzi, and M.M. Graham Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose and FDG: Analysis of the FDG lumped constant J Nucl Med 39 1998 440 448
114. J.G. Rajendran, D.C. Wilson, and E.U. Conrad [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: Correlation of hypoxia, metabolism and VEGF expression Eur J Nucl Med Mol Imaging 30 2003 695 704
115. C.S. Dence, D.E. Ponde, and M.J. Welch Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer Nucl Med Biol 35 2008 713 720
116. W. Chen, T. Cloughesy, and N. Kamdar Imaging proliferation in brain tumors with 18f-FLT PET: Comparison with 18f-FDG J Nucl Med 46 2005 945 952
117. A.F. Shields, J.R. Grierson, and B.M. Dohmen Imaging proliferation in vivo with [F-18]FLT and positron emission tomography Nat Med 4 1998 1334 1336
118. F. Dehdashti, P.W. Grigsby, and J.S. Lewis Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone) J Nucl Med 49 2008 201 205
119. F. Dehdashti, P.W. Grigsby, and M.A. Mintun Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60cu-ATSM: Relationship to therapeutic response - A preliminary report Int J Radiat Oncol Biol Phys 55 2003 1233 1238
120. F. Dehdashti, M.A. Mintun, and J.S. Lewis In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM Eur J Nucl Med Mol Imaging 30 2003 844 850
121. D.W. Dietz, F. Dehdashti, and P.W. Grigsby Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: A pilot study Dis Colon Rectum 51 2008 1641 1648
122. Y. Fujibayashi, H. Taniuchi, and Y. Yonekura Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential J Nucl Med 38 1997 1155 1160
123. A.L. Vavere, and J.S. Lewis Cu-ATSM: A radiopharmaceutical for the pet imaging of hypoxia Dalton Trans 2007 4893 4902
124. T. Hatano, S. Zhao, and Y. Zhao Biological characteristics of intratumoral [F-18]fluoromisonidazole distribution in a rodent model of glioma Int J Oncol 42 2013 823 830
125. H. De Clermont, A. Huchet, and F. Lamare Lack of concordance between the F-18 fluoromisonidazole PET and the F-18 FDG PET in human glioblastoma Clin Nucl Med 36 2011 e194 e195
126. J. Gerdes, L. Li, and C. Schlueter Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67 Am J Pathol 138 1991 867 873
127. T. Haerslev, G.K. Jacobsen, and K. Zedeler Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas Breast Cancer Res Treat 37 1996 101 113
128. T. Moriki, T. Takahashi, and H. Kataoka Proliferation marker Mib-1 correlates well with Proliferative Activity Evaluated by Brdu in Breast Cancer: An Immunohistochemical Study Including Correlation with Pcna, P53, C-Erbb-2 and Estrogen Receptor Status Pathol Int 46 1996 953 961
129. T. Scholzen, and J. Gerdes The Ki-67 protein: From the known and the unknown J Cell Physiol 182 2000 311 322
130. R.J. Boado, K.L. Black, and W.M. Pardridge Gene expression of GLUT3 and GLUT1 glucose transporters in human brain tumors Brain Res Mol Brain Res 27 1994 51 57
131. C.F. Burant, W.I. Sivitz, and H. Fukumoto Mammalian glucose transporters: Structure and molecular regulation Recent Prog Horm Res 47 1991 348 349
132. T. Nishioka, Y. Oda, and Y. Seino Distribution of the glucose transporters in human brain tumors Cancer Res 52 1992 3972 3979
133. T. Yamamoto, Y. Seino, and H. Fukumoto Over-expression of facilitative glucose transporter genes in human cancer Biochem Biophys Res Commun 170 1990 223 230
134. S.B. Fox, R.D. Leek, and M.P. Weekes Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, chalkley count, and computer image analysis J Pathol 177 1995 275 283
135. J. Hasan, R. Byers, and G.C. Jayson Intra-tumoural microvessel density in human solid tumours Br J Cancer 86 2002 1566 1577
136. J.D. Jacquemier, F.M. Penault-Llorca, and F. Bertucci Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: A multiparametric and immunohistochemical analysis J Pathol 184 1998 130 135
137. M.A. Rubin, M. Buyyounouski, and E. Bagiella Microvessel density in prostate cancer: Lack of correlation with tumor grade, pathologic stage, and clinical outcome Urology 53 1999 542 547
138. N. Weidner, J.P. Semple, and W.R. Welch Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma N Engl J Med 324 1991 1 8
139. P.J. Ratcliffe From erythropoietin to oxygen: Hypoxia-inducible factor hydroxylases and the hypoxia signal pathway Blood Purif 20 2002 445 450
140. M. Isobe, B.S. Emanuel, and D. Givol Localization of gene for human P53 tumour antigen to band 17p13 Nature 320 1986 84 85
141. S.E. Kern, K.W. Kinzler, and A. Bruskin Identification of p53 as a sequence-specific DNA-binding protein Science 252 1991 1708 1711
142. G. Matlashewski, P. Lamb, and D. Pim Isolation and characterization of a human p53 cDNA clone: Expression of the human p53 gene EMBO J 3 1984 3257 3262
143. O.W. McBride, D. Merry, and D. Givol The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13) Proc Natl Acad Sci U S A 83 1986 130 134
144. H. Arshad, Z. Ahmad, and S.H. Hasan Gliomas: Correlation of histologic grade, Ki67 and P53 expression with patient survival Asian Pac J Cancer Prev 11 2010 1637 1640
145. P.W. Grigsby, R.S. Malyapa, and R. Higashikubo Comparison of molecular markers of hypoxia and imaging with (60)Cu-ATSM in cancer of the uterine cervix Mol Imaging Biol 9 2007 278 283
146. B. Kaur, F.W. Khwaja, and E.A. Severson Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis Neuro Oncol 7 2005 134 153
147. N. Kawai, W. Lin, and W.D. Cao Correlation between F-fluoromisonidazole PET and expression of HIF-1alpha and VEGF in newly diagnosed and recurrent malignant gliomas Eur J Nucl Med Mol Imaging 41 2014 1870 1878
148. A. Fyles, M. Milosevic, and D. Hedley Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer J Clin Oncol 20 2002 680 687
149. M. Hockel, K. Schlenger, and B. Aral Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix Cancer Res 56 1996 4509 4515
150. 2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix Radiother Oncol 53 1999 99 104
151. K. Sundfor, H. Lyng, and C.G. Trope Treatment outcome in advanced squamous cell carcinoma of the uterine cervix: Relationships to pretreatment tumor oxygenation and vascularization Radiother Oncol 54 2000 101 107
152. G. Haensgen, U. Krause, and A. Becker Tumor hypoxia, p53, and prognosis in cervical cancers Int J Radiat Oncol Biol Phys 50 2001 865 872
153. E.K. Rofstad, K. Sundfor, and H. Lyng Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis Br J Cancer 83 2000 354 359
154. V. Rudat, B. Vanselow, and P. Wollensack Repeatability and prognostic impact of the pretreatment pO(2) histography in patients with advanced head and neck cancer Radiother Oncol 57 2000 31 37
155. T.G. Wendt, and P. Bank Prognostic factors in squamous cell carcinoma of the head and neck Onkologie 25 2002 208 212
156. T. Narita, H. Aoyama, and K. Hirata Reoxygenation of glioblastoma multiforme treated with fractionated radiotherapy concomitant with temozolomide: Changes defined by 18f-fluoromisonidazole positron emission tomography: Two case reports Jpn J Clin Oncol 42 2012 120 123
157. S. de Bouard, P. Herlin, and J.G. Christensen Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma Neuro Oncol 9 2007 412 423
158. R.H. Goldbrunner, M. Bendszus, and J. Wood PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization Neurosurgery 55 2004 426 432 [discussion 432]
159. K.J. Kim, B. Li, and J. Winer Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo Nature 362 1993 841 844
160. P. Kunkel, U. Ulbricht, and P. Bohlen Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2 Cancer Res 61 2001 6624 6628
161. H. Miletic, S.P. Niclou, and M. Johansson Anti-VEGF therapies for malignant glioma: Treatment effects and escape mechanisms Expert Opin Ther Targets 13 2009 455 468
162. S. Ran, X. Huang, and A. Downes Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy Neoplasia 5 2003 297 307
163. J.L. Rubenstein, J. Kim, and T. Ozawa Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption Neoplasia 2 2000 306 314
164. M. Sandstrom, M. Johansson, and U. Andersson The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model Br J Cancer 91 2004 1174 1180
165. J.J. Verhoeff, O. van Tellingen, and A. Claes Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme BMC Cancer 9 2009 444
166. R. Rahman, S. Smith, and C. Rahman Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma J Oncol 2010 2010 251231
167. R.K. Jain Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy Nat Med 7 2001 987 989
168. J.R. Flynn, L. Wang, and D.L. Gillespie Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme Cancer 113 2008 1032 1042
169. B.E. Lally, S. Rockwell, and D.B. Fischer The interactions of polarographic measurements of oxygen tension and histological grade in human glioma Cancer J 12 2006 461 466
170. L. Oliver, C. Olivier, and F.B. Marhuenda Hypoxia and the malignant glioma microenvironment: regulation and implications for therapy Curr Mol Pharmacol 2 2009 263 284
171. R.F. Spetzler, and N.A. Martin A proposed grading system for arteriovenous malformations J Neurosurg 65 1986 476 483
172. R. Sawaya Extent of resection in malignant gliomas: A critical summary J Neurooncol 42 1999 303 305
173. L.A. Stewart Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials Lancet 359 2002 1011 1018
174. K. Hirata, S. Terasaka, and T. Shiga (1)(8)F-fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas Eur J Nucl Med Mol Imaging 39 2012 760 770
175. D. Thorwarth, S.M. Eschmann, and F. Paulsen A kinetic model for dynamic [18F]-FMISO PET data to analyse tumour hypoxia Phys Med Biol 50 2005 2209 2224
176. 2O J Nucl Med 45 2004 1851 1859
177. S.C. Huang, R.E. Carson, and E.J. Hoffman An investigation of a double-tracer technique for positron computerized tomography J Nucl Med 23 1982 816 822
178. A. Andreyev, and A. Celler Dual-isotope PET using positron-gamma emitters Phys Med Biol 56 2011 4539 4556
179. N.F. Black, S. McJames, and D.J. Kadrmas Rapid multi-tracer PET tumor imaging with F-FDG and secondary shorter-lived tracers IEEE Trans Nucl Sci 56 2009 2750 2758
180. Cheng X, Navab N, Ziegler S, et al. Direct Parametric Image Reconstruction of Rapid Multi-Tracer PET, in (eds): (ed), Berlin, Heidelberg, Springer, 2013
181. F. Gao, H. Liu, and Y. Jian Dynamic dual-tracer PET reconstruction Inf Process Med Imaging 21 2009 38 49
182. D.J. Kadrmas, and T.C. Rust Feasibility of rapid multitracer PET tumor imaging IEEE Transactions on Nucl Sci 52 2005 1341 1347
183. D.J. Kadrmas, T.C. Rust, and J.M. Hoffman Single-scan dual-tracer FLT+FDG PET tumor characterization Phys Med Biol 58 2013 429 449
184. J. Tian, X. Yang, and L. Yu A multicenter clinical trial on the diagnostic value of dual-tracer PET/CT in pulmonary lesions using 3'-deoxy-3'-18F-fluorothymidine and 18F-FDG J Nucl Med 49 2008 186 194
185. C. Bell, S. Rose, and S. Puttick Dual acquisition of 18F-FMISO and 18F-FDOPA Phys Med Biol 59 2014 3925 3949
186. E.G. Troost, P. Laverman, and J.H. Kaanders Imaging hypoxia after oxygenation-modification: Comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors Radiother Oncol 80 2006 157 164